ESSA Pharma Inc.
ESSA Pharma Inc. (EPIX) Revenue
Annual & quarterly revenue history · segment & region breakdown
EPIX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsESSA Pharma Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2024.
Revenue trend
2024 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-09-30 | $0.00B | +$0.00B | — |
| 2023-09-30 | $0.00B | +$0.00B | — |
| 2022-09-30 | $0.00B | +$0.00B | — |
| 2021-09-30 | $0.00B | +$0.00B | — |
| 2020-09-30 | $0.00B | +$0.00B | — |
| 2019-09-30 | $0.00B | +$0.00B | — |
| 2018-09-30 | $0.00B | +$0.00B | — |
| 2017-09-30 | $0.00B | -$0.00B | -100.00% |
| 2016-09-30 | $0.00B | +$0.00B | — |
| 2015-09-30 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ESSA Pharma Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ESSA Pharma Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ESSA Pharma Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
EPIX revenue · 4 questionsEPIX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2024.
▸ Source: FMP · ESSA Pharma Inc. SEC filings · GAAP · ESSA Pharma Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026